{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T02:22:35Z","timestamp":1771035755731,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Society of Cytopathology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jasc.2023.01.003","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T11:47:50Z","timestamp":1673437670000},"page":"189-196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Significant outcomes associated with high-risk human papillomavirus negative Papanicolaou tests"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7542-739X","authenticated-orcid":false,"given":"Selda","family":"Karaaslan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas L.","family":"Dilcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Abdelsayed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8876-4894","authenticated-orcid":false,"given":"Abha","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jasc.2023.01.003_bib1","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/COC.0000000000000264","article-title":"Impact of widespread cervical cancer screening: number of cancers prevented and changes in race-specific incidence","volume":"41","author":"Yang","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jasc.2023.01.003_bib2","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jasc.2023.01.003_bib4","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(11)70145-0","article-title":"Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice","volume":"12","author":"Katki","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jasc.2023.01.003_bib5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jama.2018.7464","article-title":"Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: the HPV FOCAL randomized clinical trial","volume":"320","author":"Ogilvie","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jasc.2023.01.003_bib6","doi-asserted-by":"crossref","first-page":"a1754","DOI":"10.1136\/bmj.a1754","article-title":"Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study","volume":"337","author":"Dillner","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jasc.2023.01.003_bib7","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1001\/jama.285.11.1500","volume":"285","author":"Stoler","year":"2001","journal-title":"JAMA"},{"issue":"Suppl 5","key":"10.1016\/j.jasc.2023.01.003_bib8","doi-asserted-by":"crossref","first-page":"F24","DOI":"10.1016\/j.vaccine.2012.05.089","article-title":"Updating the natural history of human papillomavirus and anogenital cancers","volume":"30","author":"Moscicki","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.jasc.2023.01.003_bib9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/LGT.0b013e31824ca9d5","article-title":"American cancer society, American society for colposcopy and cervical pathology, and American society for clinical pathology screening guidelines for the prevention and early detection of cervical cancer","volume":"16","author":"Saslow","year":"2012","journal-title":"J Low Genit Tract Dis"},{"key":"10.1016\/j.jasc.2023.01.003_bib10","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/LGT.0000000000000525","article-title":"2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors","volume":"24","author":"Perkins","year":"2020","journal-title":"J Low Genit Tract Dis"},{"key":"10.1016\/j.jasc.2023.01.003_bib11","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/LGT.0b013e3181585870","article-title":"ASCCP-sponsored consensus conference. 2006 consensus guidelines for the management of women with abnormal cervical screening tests","volume":"11","author":"Wright","year":"2007","journal-title":"J Low Genit Tract Dis"},{"key":"10.1016\/j.jasc.2023.01.003_bib12","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/cncy.21480","article-title":"Primary human papillomavirus screening for cervical cancer in the United States-US food and drug administration approval, clinical trials, and where we are today","volume":"122","author":"Nayar","year":"2014","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.jasc.2023.01.003_bib13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/LGT.0000000000000103","article-title":"Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance","volume":"19","author":"Huh","year":"2015","journal-title":"J Low Genit Tract Dis"},{"key":"10.1016\/j.jasc.2023.01.003_bib14","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1001\/jama.2018.10897","article-title":"Screening for cervical cancer: US preventive services task force recommendation statement","volume":"320","author":"Curry","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jasc.2023.01.003_bib15","first-page":"321","article-title":"Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society","volume":"70","author":"Fontham","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jasc.2023.01.003_bib16","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jasc.2018.08.005","article-title":"An advocacy victory: final USPSTF cervical cancer screening recommendations revised to include cotesting option","volume":"7","author":"Davey","year":"2018","journal-title":"J Am Soc Cytopathol"},{"key":"10.1016\/j.jasc.2023.01.003_bib17","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jasc.2017.12.001","article-title":"Primary HPV cervical cancer screening in the United States: are we ready?","volume":"7","author":"Nayar","year":"2018","journal-title":"J Am Soc Cytopathol"},{"key":"10.1016\/j.jasc.2023.01.003_bib18","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/ajcp\/aqaa074","article-title":"Contributions of liquid-based (Papanicolaou) cytology and human papillomavirus testing in cotesting for detection of cervical cancer and precancer in the United States","volume":"154","author":"Kaufman","year":"2020","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jasc.2023.01.003_bib19","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/cncy.21544","article-title":"Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices","volume":"123","author":"Blatt","year":"2015","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.jasc.2023.01.003_bib20","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jasc.2019.01.001","article-title":"HPV status in women with high-grade dysplasia on cervical biopsy and preceding negative HPV tests","volume":"8","author":"Ge","year":"2019","journal-title":"J Am Soc Cytopathol"},{"key":"10.1016\/j.jasc.2023.01.003_bib21","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jasc.2020.04.010","article-title":"HPV detection rates and histopathologic follow-up of patients with HSIL cytology in a large academic women's hospital laboratory","volume":"9","author":"Ashman","year":"2020","journal-title":"J Am Soc Cytopathol"},{"key":"10.1016\/j.jasc.2023.01.003_bib22","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/dc.23959","article-title":"High grade squamous intraepithelial lesion on high-risk HPV negative patients: Why we still need the pap test","volume":"46","author":"Sun","year":"2018","journal-title":"Diagn Cytopathol"},{"key":"10.1016\/j.jasc.2023.01.003_bib23","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1001\/jama.287.16.2114","article-title":"The 2001 bethesda system: terminology for reporting results of cervical cytology","volume":"287","author":"Solomon","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jasc.2023.01.003_bib24","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000381842","article-title":"\u201cThe reports of my demise have been greatly exaggerated.\u201d (after a quotation from Mark Twain)","volume":"59","author":"Nayar","year":"2015","journal-title":"Acta Cytol"},{"key":"10.1016\/j.jasc.2023.01.003_bib25","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jasc.2019.06.001","article-title":"A review of the FDA-approved molecular testing platforms for human papillomavirus","volume":"8","author":"Salazar","year":"2019","journal-title":"J Am Soc Cytopathol"},{"key":"10.1016\/j.jasc.2023.01.003_bib26","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.5858\/arpa.2018-0603-CP","article-title":"Bethesda 2014 implementation and human papillomavirus primary screening: practices of laboratories participating in the college of American pathologists PAP education program","volume":"143","author":"Davey","year":"2019","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jasc.2023.01.003_bib27","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/jnci\/djx225","article-title":"Relative performance of HPV and cytology components of cotesting in cervical screening","volume":"110","author":"Schiffman","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jasc.2023.01.003_bib28","doi-asserted-by":"crossref","first-page":"688","DOI":"10.5858\/arpa.2018-0001-RA","article-title":"Primary high-risk human papillomavirus testing for cervical cancer screening in the United States: is it time?","volume":"142","author":"Flanagan","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jasc.2023.01.003_bib29","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1128\/JCM.01087-15","article-title":"Point-counterpoint: cervical cancer screening should be done by primary human papillomavirus testing with genotyping and reflex cytology for women over the age of 25 years","volume":"53","author":"Stoler","year":"2015","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jasc.2023.01.003_bib30","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/ajcp\/aqaa198","article-title":"Cervical screening performance","volume":"155","author":"Schiffman","year":"2021","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jasc.2023.01.003_bib31","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1309\/AJCPM9X5RCZYEQJQ","article-title":"Low-grade squamous intraepithelial lesion\/cannot exclude high-grade squamous intraepithelial lesion (LSIL-H) is a unique category of cytologic abnormality associated with distinctive HPV and histopathologic CIN 2+ detection rates","volume":"141","author":"Barron","year":"2014","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jasc.2023.01.003_bib32","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1309\/QRDNMWWAKJQTVJGF","article-title":"\u201cLow-grade squamous intraepithelial lesion, cannot exclude high-grade squamous intraepithelial lesion\u201d is a distinct cytologic category: histologic outcomes and HPV prevalence","volume":"128","author":"Owens","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jasc.2023.01.003_bib33","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1309\/AJCPYK60BZRNNAHQ","article-title":"Follow-up outcomes in a large cohort of patients with human papillomavirus-negative ASC-H cervical screening test results","volume":"138","author":"Cohen","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jasc.2023.01.003_bib34","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jasc.2015.01.005","article-title":"HPV testing results and histologic follow-up in women with ASC-H cytology in different age groups","volume":"4","author":"Chen","year":"2015","journal-title":"J Am Soc Cytopathol"},{"key":"10.1016\/j.jasc.2023.01.003_bib35","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/cncr.21388","article-title":"Atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion: diagnostic performance, human papillomavirus testing, and follow-up results","volume":"108","author":"Srodon","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.jasc.2023.01.003_bib36","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/AOG.0b013e3181e3e719","article-title":"The age-specific relationships of abnormal cytology and human papillomavirus DNA results to the risk of cervical precancer and cancer","volume":"116","author":"Castle","year":"2010","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jasc.2023.01.003_bib37","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1093\/ajcp\/aqv085","article-title":"The value of Papanicolaou tests in the diagnosis of endometrial carcinoma: a large study cohort from an academic medical center","volume":"145","author":"Serdy","year":"2016","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jasc.2023.01.003_bib38","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/cncy.22266","article-title":"Sensitivity of cervico-vaginal cytology in endometrial carcinoma: a systematic review and meta-analysis","volume":"128","author":"Frias-Gomez","year":"2020","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.jasc.2023.01.003_bib39","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/PAS.0000000000000986","article-title":"International endocervical adenocarcinoma criteria and classification (IECC): a new pathogenetic classification for invasive adenocarcinomas of the endocervix","volume":"42","author":"Stolnicu","year":"2018","journal-title":"Am J Surg Pathol"}],"container-title":["Journal of the American Society of Cytopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213294523000030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213294523000030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T06:47:17Z","timestamp":1761979637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213294523000030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S2213294523000030"],"URL":"https:\/\/doi.org\/10.1016\/j.jasc.2023.01.003","relation":{},"ISSN":["2213-2945"],"issn-type":[{"value":"2213-2945","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Significant outcomes associated with high-risk human papillomavirus negative Papanicolaou tests","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Society of Cytopathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jasc.2023.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Society of Cytopathology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}